Condition: Esophageal Squamous Cell Carcinoma · Esophageal Squamous Dysplasia · Sponsor: University of California, San Francisco
In the current protocol, we propose a study to evaluate a novel, combined esophageal sponge-methylation biomarker strategy for the early detection of esophageal squamous cell carcinoma (ESCC) as well as its precursor, esophageal squamous dysplasia (ESD). This strategy leverages the 'EsophaCap', a swallowable, retrievable sponge, with subsequent evaluation of the sample using a novel molecular biomarker assay. This biomarker assay evaluates methylation levels in select genes, which have been shown to differ significantly between ESCC cases and controls in pilot studies. Detection of methylation markers highly associated with ESCC could help identify patients with concurrent ESCC or at high risk of imminently developing this condition. If successful, this strategy could result in a paradigm shift for esophageal cancer control strategies in Tanzania and other high-incidence ESCC regions.
This description comes directly from the study's public registry record.
Geoffrey Buckle, MD, MPH · 508-380-9129 · geoffrey.buckle@ucsf.edu
Always discuss trial participation with your own doctor first.
| Muhimbili National Hospital (MNH) | Dar es Salaam, Mloganzila, Tanzania | Recruiting |
| Muhimbili National Hospital (MNH) | Dar es Salaam, Upganda, Tanzania | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05028725